LB Pharmaceuticals Statistics
Total Valuation
LBRX has a market cap or net worth of $899.84 million. The enterprise value is $608.20 million.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LBRX has 28.68 million shares outstanding. The number of shares has increased by 2,145.81% in one year.
| Current Share Class | 28.68M |
| Shares Outstanding | 28.68M |
| Shares Change (YoY) | +2,145.81% |
| Shares Change (QoQ) | +337.52% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 64.19% |
| Float | 19.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.63 |
| P/TBV Ratio | 2.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.44, with a Debt / Equity ratio of 0.01.
| Current Ratio | 41.44 |
| Quick Ratio | 39.67 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.70% and return on invested capital (ROIC) is -11.23%.
| Return on Equity (ROE) | -15.70% |
| Return on Assets (ROA) | -10.64% |
| Return on Invested Capital (ROIC) | -11.23% |
| Return on Capital Employed (ROCE) | -9.66% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$933,519 |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LBRX has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 25.80 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 65.35 |
| Average Volume (20 Days) | 322,453 |
Short Selling Information
The latest short interest is 3.11 million, so 10.85% of the outstanding shares have been sold short.
| Short Interest | 3.11M |
| Short Previous Month | 2.62M |
| Short % of Shares Out | 10.85% |
| Short % of Float | 15.78% |
| Short Ratio (days to cover) | 9.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.50M |
| Pretax Income | -25.20M |
| Net Income | -25.21M |
| EBITDA | -29.18M |
| EBIT | -29.50M |
| Earnings Per Share (EPS) | -$3.13 |
Full Income StatementBalance Sheet
The company has $295.21 million in cash and $3.57 million in debt, giving a net cash position of $291.64 million or $10.17 per share.
| Cash & Cash Equivalents | 295.21M |
| Total Debt | 3.57M |
| Net Cash | 291.64M |
| Net Cash Per Share | $10.17 |
| Equity (Book Value) | 301.31M |
| Book Value Per Share | 11.91 |
| Working Capital | 300.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.21 million and capital expenditures -$52,000, giving a free cash flow of -$35.26 million.
| Operating Cash Flow | -35.21M |
| Capital Expenditures | -52,000 |
| Depreciation & Amortization | 321,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -35.26M |
| FCF Per Share | -$1.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |